J Am Coll Cardiol 70(16):20222035 Saglietto A, Falasconi G, Penela D, Francia P, Sau A, Ng FS et al (2024) Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: a systematic review and meta-analysis
Louis Aronne, MD, FACP, an expert in weight management and GLP-1 therapy, and are suitable for people using GLP-1 medications or cutting calories to lose weight by addressing nutrient deficiencies that commonly occur during weight loss
So a product can be legally on sale and still be clinically unproven, which is precisely the gap that marketing hides in
Glp one in Louisiana provides a sense of security that other programs often lack
Diarrhea Paradoxically, semaglutide can cause both constipation and diarrhea
You can test for free at a Quest location or order a $75 at-home kit